Gilead's total revenues were $26.1 billion in 2017
For the fourth quarter 2017, Gilead Sciences announces $5.9 billion total revenues. For the full year 2017, total revenues were $26.1 billion. Product sales for the fourth quarter were $5.8 billion and $25.7 billion for the full year. HIV and HBV product sales for the full year 2017 were $14.2 billion compared to $12.9 billion in 2016. The increase was primarily due to the strong uptake of Gilead's TAF-based regimens which now account for 62% of Gilead's total HIV prescription volume in the U.S.
At the end of 2017, Genvoya remained the most prescribed HIV therapy for treatment naive and switch patients in the U.S. and across the top five European markets. Genvoya represents the most successful HIV launch in the U.S. and is the first HIV product to reach $3 billion in annual sales.
In Europe, sales of Gilead's TAF-based regimens continue to grow, while generic TDF and TDF/FTC are available in several countries. Truvada for PrEP has remained a growth driver for Gilead. At the end of last year, approximately 153,000 people in the U.S. were taking Truvada for this indication, representing a greater than fivefold increase since January 2015.
HCV product sales were $9.1 billion compared to $14.8 billion in 2016. The arrival of new competition, along with fewer patient starts, contributed to the year-over-year decline.
Finally, other product sales were $2.3 billion compared to $2.2 billion in 2016.